First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx
First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx
First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
1:1<br />
Study treatment and schedule<br />
Recruitment<br />
Randomisation<br />
ALX-0081<br />
Placebo<br />
Prior to<br />
first PE<br />
single<br />
i.v. bolus<br />
(10 mg)<br />
Treatment phase<br />
PE period<br />
s.c. doses<br />
(10 mg)<br />
1 or 2/day<br />
based on RiCo<br />
assay<br />
Post-PE<br />
(30 days)<br />
s.c. doses<br />
(10 mg)<br />
1 or 2/day<br />
based on RiCo<br />
assay<br />
Follow-up<br />
(1 year)<br />
Primary endpoint Secondary endpoints<br />
18
Change language